Johnson & Johnson Inc has declared its €24.75 per-share offer for Crucell NV, the Dutch developer of therapeutic and prophylactic vaccines, unconditional. Crucell will now operate as a vaccine centre within J&J. The two companies announced completion of the merger on 22 February 2011.
